End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
38.98 CNY | -2.21% | +6.13% | +34.46% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- The company shows low valuation levels, with an enterprise value at 0.3 times its sales.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company sustains low margins.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+34.46% | 2.82B | D+ | ||
+21.93% | 72.24B | C+ | ||
+7.33% | 8.92B | C | ||
+10.34% | 8.58B | B | ||
-19.80% | 8.07B | B- | ||
+14.16% | 5.24B | B- | ||
+12.70% | 4.24B | B+ | ||
-0.03% | 4.15B | B- | ||
-2.54% | 3.92B | B | ||
+24.00% | 3.75B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 000028 Stock
- Ratings China National Accord Medicines Corporation Ltd.